AXDX - Accelerate Diagnostics, Inc.
| Previous Close | 13.26 |
| Open | 12.85 |
| Bid | 13.03 x 1200 |
| Ask | 13.08 x 800 |
| Day's Range | 12.72 - 13.38 |
| 52 Week Range | 12.72 - 30.35 |
| Volume | 294,625 |
| Avg. Volume | 314,075 |
| Market Cap | 704.583M |
| Beta (3Y Monthly) | 3.85 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.50 |
| Earnings Date | Nov 7, 2017 - Nov 13, 2017 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 18.33 |
- Thomson Reuters StreetEvents•1 hour ago
Edited Transcript of AXDX earnings conference call or presentation 6-Nov-18 9:15pm GMT
Q3 2018 Accelerate Diagnostics Inc Earnings Call
Markit•5 days agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
Markit•11 days agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. Over the last one-month, outflows of investor capital in ETFs holding AXDX totaled $191 million.
- GlobeNewswire•11 days ago
Analysis: Positioning to Benefit within CSS Industries, Accelerate Diagnostics, Oasis Petroleum, Model N, Carbonite, and Masonite International — Research Highlights Growth, Revenue, and Consolidated Results
NEW YORK, Nov. 09, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
- Zacks•14 days ago
Accelerate Diagnostics (AXDX) Reports Q3 Loss, Lags Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of 6.82% and -53.05%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•14 days ago
Accelerate Diagnostics: 3Q Earnings Snapshot
On a per-share basis, the Tucson, Arizona-based company said it had a loss of 41 cents. The results beat Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- PR Newswire•14 days ago
Accelerate Diagnostics reports Q3 2018 financial results
Revenue Placements up 40 Percent in U.S., Total Revenue up 64 Percent TUCSON, Ariz. , Nov. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending ...
- Zacks•21 days ago
Earnings Preview: Accelerate Diagnostics (AXDX) Q3 Earnings Expected to Decline
Accelerate Diagnostics (AXDX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Markit•26 days agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Short interest is extremely high for AXDX with more than 20% of shares on loan. This means that investors who seek to profit from falling equity prices are currently targeting AXDX. The net inflows of $1.30 billion over the last one-month into ETFs that hold AXDX are not among the highest of the last year and have been slowing.
- PR Newswire•last month
Accelerate Diagnostics to Review Third Quarter 2018 Results on November 6th
TUCSON, Ariz. , Oct. 17, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it will host a conference call on Tuesday, November 6, 2018 to review the company's third quarter 2018 financial ...
- GlobeNewswire•last month
Factors of Influence in 2018, Key Indicators and Opportunity within Meritor, Fred's, Arena Pharmaceuticals, AMERISAFE, Accelerate Diagnostics, and NextEra Energy — New Research Emphasizes Economic Growth
NEW YORK, Oct. 15, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
- Zacks•last month
Accelerate Diagnostics (AXDX) Surges: Stock Moves 6% Higher
Accelerate Diagnostics (AXDX) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
- PR Newswire•2 months ago
Accelerate Diagnostics announces resignation of Joan Martin as Head of Europe, Middle East, and Africa
TUCSON, Ariz. , Sept. 27, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that Joan Martin resigned from his position as Executive Vice President and Head of Europe , Middle East , and ...
Markit•2 months agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
Markit•2 months agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
Markit•3 months agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
Markit•3 months agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
- Thomson Reuters StreetEvents•3 months ago
Edited Transcript of AXDX earnings conference call or presentation 6-Aug-18 8:15pm GMT
Q2 2018 Accelerate Diagnostics Inc Earnings Call
Markit•3 months agoSee what the IHS Markit Score report has to say about Accelerate Diagnostics Inc.
Accelerate Diagnostics Inc NASDAQ:AXDX
- PR Newswire•3 months ago
Accelerate Diagnostics Receives New Innovative Technology Contract from Vizient for the Accelerate Pheno™ System
TUCSON, Ariz., Aug. 7, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. announced today that it received an Innovative Technology contract from Vizient, Inc., the largest member-driven health care performance improvement company in the United States. The contract was based on a recommendation of the Accelerate Pheno™ system by hospital experts in this category who serve on one of Vizient's member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization's care delivery and business model. "We're honored that our technology was awarded this Innovative Technology contract, enabling it to be on contract without waiting for the next competitive bid cycle," said Marilyn Drake, Director of Corporate Business for Accelerate Diagnostics.
- Zacks•3 months ago
Accelerate Diagnostics (AXDX) Reports Q2 Loss, Misses Revenue Estimates
Accelerate Diagnostics (AXDX) delivered earnings and revenue surprises of -16.22% and -22.03%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
- Associated Press•3 months ago
Accelerate Diagnostics: 2Q Earnings Snapshot
The Tucson, Arizona-based company said it had a loss of 43 cents per share. The results fell short of Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...
- PR Newswire•3 months ago
Accelerate Diagnostics reports Q2 2018 financial results
Revenue up 142 Percent, Global install base up 25 Percent TUCSON, Ariz. , Aug. 6, 2018 /PRNewswire/ -- Accelerate Diagnostics, Inc. today announced financial results for the quarter ending June 30 , 2018. ...
- ACCESSWIRE•3 months ago
Accelerate Diagnostics, Inc. to Host Earnings Call
NEW YORK, NY / ACCESSWIRE / August 6, 2018 / Accelerate Diagnostics, Inc. (NASDAQ: AXDX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 6, 2018 at 4:15 PM Eastern ...
